January 1, 1998Japanese Circulation Journal-english EditionOpen Access

Ischemic and Non-Ischemic Myocyte Damage and Antimyosin Monoclonal Imaging

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

TNTomoaki NakataCardiac Imaging KSKazuaki ShimamotoPreventive Cardiology

Discussion

Member takes

Implication

May support acute necrosis assessment; leaves open reliable role in chronic cardiomyopathy pending prospective data.

Structured PICO

Intervention

Antimyosin monoclonal antibody imaging

Antimyosin monoclonal antibody imaging serves as a specific marker for both acute myocardial necrosis and ongoing myocardial degeneration, aiding in early detection of myocardial damage.

Limitations

Requires further progress in immunologic and radiolabeling techniques for better specificity and less antigenicity against humans

Cite This Study

Nakata et al. (1998) studied this question.

synapsesocial.com/papers/6a91a7aceb737fc72043daeb https://doi.org/10.1253/jcj.62.77

View Full Paper

Ask AI

Bookmark

Ischemic and Non-Ischemic Myocyte Damage and Antimyosin Monoclonal Imaging

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Ischemic and Non-Ischemic Myocyte Damage and Antimyosin Monoclonal Imaging

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider